In addition, targeted therapy drugs such as tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are used to treat NSCLC patients [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.